支持骨质疏松治疗指南的随机对照试验结果脆弱性:回顾性分析
该回顾性分析首次评估支持骨质疏松治疗指南的随机对照试验(RCT)结果的脆弱性。从指南中识别372项RCT,42项符合条件,中位脆弱指数(FI)为10,中位脆弱商(FQ)为0.007,约三分之一RCT的FI≤5,17项(40.5%)试验的失访患者数大于FI。结论认为部分RCT结果依赖少量事件,FI和FQ可提供直观指标帮助解读试验结果的稳健性。
要点
- 支持骨质疏松指南的RCT结果通常统计上脆弱,中位FI仅10。
- 约三分之一RCT的FI≤5,40.5%试验失访数超过FI。
- FI与样本量、期刊影响因子和失访百分比显著相关。
核心结论
- 部分支持骨质疏松治疗指南推荐的RCT结果依赖少量事件,统计上脆弱。
- FI和FQ可作为额外直观指标帮助解读试验结果的稳健性。
研究设计与样本
- 回顾性分析,从骨质疏松治疗指南中识别RCT,纳入研究原发性骨质疏松、1:1随机分组、以骨折结局为主要终点的试验。
- 共识别372项RCT,42项符合条件纳入分析。
主要发现
- 42项RCT的中位FI为10(Q1-Q3:4-18),中位FQ为0.007(Q1-Q3:0.0017-0.019)。
- 约三分之一RCT的FI≤5。
- 17项(40.5%)试验的失访患者数大于FI。
- FI与样本量、期刊影响因子和失访百分比显著相关。
关键数值与推荐
- FI定义为干预组中需要从非事件变为事件的最小事件数,以使显著结果变为不显著(或反之)。
- FQ计算为FI除以试验样本量。
临床怎么用
- 临床解读骨质疏松治疗RCT结果时,可参考FI和FQ评估稳健性。
- 注意失访患者数超过FI的试验,其结果的可靠性可能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This is the first report on the fragility of results from randomized controlled trials (RCTs) for the treatment of osteoporosis. The results of aforementioned RCTs appear to depend on a small number of events and are generally statistically fragile. INTRODUCTION: Osteoporosis remains a health concern worldwide. Evidence-based guideline recommendations that are mainly based on results of clinical trials are important to clinical decision-making. The fragility index (FI) is a novel statistical metric to measure the fragility of results from an RCT. Our study aimed to analyze the fragility of the clinical trials referenced in the guidelines for the treatment of osteoporosis. METHODS: Trials were included if they investigated primary osteoporosis, randomized patients to treatment or control in a 1:1 design, and reported fracture outcome as the primary endpoint. The FI and fragility quotient (FQ) were calculated for assessing the robustness of results from the eligible RCTs. An FI was defined as the minimum number of events in the intervention group that needs to change from a non-event to an event in order to render a significant result non-significant (or vice versa). The FQ was calculated by dividing the FI by the sample size of the trial. RESULTS: Of the 372 RCTs identified from the guidelines, 42 were eligible for analyses. Their median FI was 10 (25th-75th percentile [Q1-Q3]: 4-18), with a median FQ of 0.007 (Q1-Q3: 0.0017-0.019). Approximately one third of the RCTs had a FI of less than or equal to 5. There were 17 (40.5%) trials where the number of patients lost to follow-up was greater than the FI. The FI was significantly associated with sample size, journal impact factor, and the percent of patients lost to follow-up. CONCLUSION: Results from some RCTs supporting guideline recommendations for the treatment of osteoporosis depend on a small number of events. The FI and FQ may provide additional, intuitive metrics to help interpret the robustness of trial results.
引用
- Huang X, Chen B, Thabane L, et al. Fragility of results from randomized controlled trials supporting the guidelines for the treatment of osteoporosis: a retrospective analysis. Osteoporos Int. 2021. PMID: 33595680. doi:10.1007/s00198-021-05865-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。